SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging


  • Org Study ID: PA13-0942
  • Secondary ID:
  • NCT ID: NCT02203136
  • NCT Alias:
  • Sponsor: M.D. Anderson Cancer Center - Other
  • Source: M.D. Anderson Cancer Center

Brief Summary

The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.

Detailed Description


If you agree to take part in the study, a piece of the tumor that is removed during the
biopsy will be collected for research purposes. The tissue will be sent to the laboratory for
genetic testing.

If you have had a computed tomography scan (CT scan) or magnetic resonance imaging scan (MRI)
recently, information collected from the scan will be collected. If you have not had one
recently, you will have an MRI with contrast as part of this study. You will receive a
separate consent form for this MRI scan.

The results of the test will be given to your doctor, but the results will not be used to
decide your treatment.

After you have surgery, information will be collected from your medical records, such as your
diagnosis.

Length of Study:

Your participation on this study will be over once your surgery is completed.

This is an investigational study.

Up to 100 participants will take part in this study. All will be enrolled at MD Anderson.

Overal Status Start Date Phase Study Type
Recruiting Start Date: June 2014 N/A Observational

Primary Outcomes:

Primary Outcome 1 - Measure: Detection Improvement of Cancer Outside of the Bladder

Primary Outcome 1 - Time Frame: 4 weeks

Condition:

  • Bladder Cancer

Eligibility

Criteria:
Inclusion Criteria:

1. Patients with biopsy proven bladder cancer of any age will be eligible for enrollment.

Exclusion Criteria:

1. Contraindication to pelvic MRI (metallic implants/hardware, claustrophobia)

2. Participants who have previously received chemotherapy as part of multimodal therapy.
Show More

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Neema Navai, MD

Role: Principal Investigator

Affiliation: M.D. Anderson Cancer Center

Overall Contact

Name: Neema Navai, MD

Phone: 713-792-3250

Email:

Link: University of Texas MD Anderson Cancer Center Website

Location

Facility Status Contact
University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
Recruiting